Apoptosis in gliomas: Molecular mechanisms and therapeutic implications

Journal of Neuro-Oncology

Volumn 70, Issue 2, 2004, Pages 245-254

  Steinbach, Joachim P ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apo2L TRAIL; Apoptosis; CD95L; EGFR; Glioma; Hypoxia; p21; p53

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BROPARESTROL; CAMPTOTHECIN; CANNABINOID DERIVATIVE; CARBOPLATIN; CARMUSTINE; CASPASE INHIBITOR; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LOMUSTINE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAC1 PROTEIN; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SALAZOSULFAPYRIDINE; TIRAPAZAMINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL CULTURE; CELL CYCLE; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; IN VIVO STUDY; MOLECULAR MECHANICS; NEUROIMAGING; NONHUMAN; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

EID: 9144253200     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11060-004-2753-4     Document Type: Review

References (81)

1. Kerr AF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972
2. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M: Hypoxia-induced cell death in human malignant glioma cells: Energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 10: 823-832, 2003
3. Steinbach JP, Weller M: Mechanisms of apoptosis in CNS tumors: application to theory. Current Neurol Neurosc Rep 2: 246-253, 2002
4. Bögler O, Weller M: Apoptosis in glioma, and its role in their current and future treatment. Front Biosci 7: E339-353, 2002
5. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223, 1996
6. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530, 1997
7. Weller M: Predicting response to canceT chemotherapy: the role of p53. Cell Tissue Res 292: 435-445, 1998
8. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J: Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int J Cancer 79: 640-644, 1998
9. Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M: Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res 61: 5833-5842, 2001
10. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5: 637-642, 1999
11. Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510, 1999
12. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22: 8233-8245, 2003
13. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814, 1997
14. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995
15. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R: BCL-2 family protein expression in initial and recurrent glioblastomas: Modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67: 763-768, 1999
16. Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M: Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene 18: 5044-5053, 1999
17. Glaser T, Weller M: Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. Biochem Biophys Res Commun 281: 322-327, 2001
18. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M: BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett 440: 419-424, 1998
19. Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P, Weller M: Adenoviral natural born killer gene therapy for malignant glioma. Hum Gene Ther 14: 1235-1246, 2003
20. Weller L, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 8: 285-293, 1998
21. Rieger A, Naumann U, Glaser T, Ashkenazi A, Weller M: APO2 ligand: a novel lethal weapon against malignant glioma? FEEBS Lett 427: 124-128, 1998
22. Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M: CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20: 4128-4137, 2001
23. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759-2765, 2001
24. Naumann U, Wick W, Beschorner R, Meyermann R, Weller M: Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 107: 17-22, 2004
25. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964, 1994
26. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M: Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55-63, 1997
27. Shinoura N, Yoshida Y, Sadata A, Hanada KI, Yamamoto S, Kirino T, Asai A, Hamada H: Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: Implications for gene therapy. Hum Gene Ther 9: 1983-1993, 1998
28. Maleniak TC, Darling JL, Lowenstein PR, Castro MG: Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther 8: 589-598, 2001
29. Glaser T, Wagenknecht B, Weller M: Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 20: 4757-4767, 2001
30. Kokunai T, Urui S, Tomita H, Tamaki N: Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide. J Neurooncol 51: 111-119, 2001
31. Ruan S, Okcu MF, Pong RC, Andreeff M, Levin V, Hsieh JT, Zhang W: Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res 5: 197-202, 1999
32. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809, 1993
33. Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR, Fontana A: Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Therapy 10: 1641-1648, 1999
34. Kondo S, Ishizaka Y, Okada T, Kondo Y, Hitomi M, Tanaka Y, Haqqi T, Barnett GH, Barna BP: FADD gene therapy for malignant gliomas in vitro and in vivo. Hum Gene Ther 9: 1599-1608, 1998
35. Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, McCormick F, Haas-ogan DA: Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene 20: 2826-2835, 2001
36. Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA: Retroviral delivery and tetracycline-dependent expression of IL-1beta- converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res 56: 5423-5427, 1996
37. Roth W, Isenmann S, Naumann U, Kugler S, Bähr M, Dichgans J, Ashkenazi A, Weller M: Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265: 479-483, 1999
38. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000
39. Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C: TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 13: 539-553, 2003
40. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K: A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 88: 298-306, 2003
41. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A: Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281, 2002
42. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960, 2001
43. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC: Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res 61: 1162-1170, 2001
44. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C: Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277: 25020-25025, 2002
45. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY: Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Therapy 10: 814-822, 2003
46. Hermisson M, Weller M: NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells. Cell Death Differ 10: 1078-1089, 2003
47. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ: Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20: 5789-5798, 2001
48. Fulda S, Wick W, Weller M, Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815, 2002
49. Amirlak B, Couldwell RT: Apoptosis in glioma cells: review and analysis of techniques used for study with focus on the laser scanning cytometer. J Neurooncol 63: 129-145, 2003
50. Leaver HA, Whittle IR, Wharton SB, Ironside JW: Apoptosis in human primary brain tumours. Br J Neurosurg 12: 539-546, 1998
51. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK: Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and Genetics of Tumours of the Nervous System, 2nd edn. IARC press, Lyon 2000, pp 29-39
52. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT, Marino S, Attanasio A: Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 195: 81-84, 1995
53. Korkolopoulou PA, Konstantinidou AE, Patsouris ES, Christodoulou PN, Thomas-Tsagli EA, Davaris PS: Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA. J Pathol 193: 377-382, 2001
54. Heesters MA, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value. J Neurooncol 44: 255-266, 1999
55. Kuriyama H, Lamborn KR, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, Buckner JC, Kuriyama N, Jenkins RB, Israel MA: Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro-oncol 4: 179-186, 2002
56. Korshunov A, Golanov A, Sycheva R, Pronin I: Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases. J Clin Pathol 52: 574-580, 1999
57. Nakamizo A, Inamura T, Ikezaki K, Yoshimoto K, Inoha S, Mizoguchi M, Amano T, Fukui M: Enhanced apoptosis inApilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors. J Neurooncol 57: 105-114, 2002
58. Wharton SB, Hamilton FA, Chan WK, Chan KK, Anderson JR: Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 24: 21-28, 1998
59. Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361, 1995
60. Tews DS: Cell death and oxidative stress in gliomas. Neuropathol Appl Neurobiol 25: 272-284, 1999
61. Kordek R, Hironishi M, Liberski PP, Yanagihara R, Gajdusek DC: Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol 91: 112-116, 1996
62. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M: BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 56: 43-49, 2002
63. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159, 2003
64. Herr I, Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001
65. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ: Drug resistance of human glioblastoma cells conferred by a turner- specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724-5729, 1998
66. Shingu T, Yamada K, Kara N, Moritake K, Osago H, Terashima, M, Uemura T, Yamasaki T, Tsuchiya M: Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63: 4044-4047, 2003
67. Chen TC, Su S, Fry D, Liebes L: Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 97: 2363-2373, 2003
68. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG: Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61: 187-196, 2003
69. Reichert M, Steinbach JP, Supra P, Weller M: Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. Cancer 95: 1113-1119, 2002
70. Brown JM: ThA hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59: 5863-5870, 1999
71. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M: Anti-tumoral action oI cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313-319, 2000
72. Senger DL, Tudan C, Guiot MC, Mazzoni IE, Molenkamp G, LeBlanc R, Antel J, Olivier A, Snipes GJ, Kaplan DR: Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res 62: 2131-2140, 2002
73. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Cancer Res 91: 7727-7731, 1994
74. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57, 2000
75. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M: CD95-mediated apoptosis of human malignant glioma cells: Modulation by epidermal growth factor receptor activity. Brain Pathol 12: 12-20, 2002
76. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002
77. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18: 7514-7526, 1999
78. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M: PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18: 3936-3943, 1999
79. Neshat MS, Mellinghoff IK, Iran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001
80. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 21: 2508-2518, 2003
81. Steinbach JP, Klumpp A, Wolburg H, Weller M: Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 64: 1570-1574, 2004